News Gilead develops solid tumour cell therapy with Gadeta Gilead has option to buy biotech if things go well
News Lilly beats Novo to China with an oral GLP-1 for obesity Lilly's orforglipron has been approved in China, becoming the first oral GLP-1 agonist to enter the Chinese weight management market.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
